The FDA released a statement on December 17, 2004 halting a clinical trial of Celebrex, a Cox-2 inhibitor. The trial was stopped because of “an increased risk of cardiovascular events in patients taking Celebrex.
Vioxx, a Cox-2 inhibitor by Merck, was voluntarily withdrawn from the market in September 2004 for an increased risk of heart attacks, strokes, and bleeds.
Patients in the Celebrex trial taking 400mg. twice daily had a 3.4 times greater risk of cardiovascular events compared to placebo.
Disclaimer:
Colorado Trial Attorney Disclaimer: Denver and Breckenridge
securities and investment fraud, business lawsuits,
construction injuries, medical malpractice, wrongful
death, brain injury, personal injury, pharmaceutical
litigation, and/or other legal information offered herein
by Gempeler Trial Attorneys is not formal legal advice,
nor the formation of an attorney client relationship.
The information provided on Gempeler Trial Lawyers'
website is intended to educate the visitors and does
not constitute legal advice. Each case is different
and the outcome of your case will depend on the merits
of your factual situation and applicable law. An Attorney-Client
relationship is not created by visiting this web site.
No Attorney-Client relationship is created until a retainer
agreement is signed.
Home
| Areas of Practice | News & Alerts | FAQ's | About
Us | Speeches & Articles
| Calendar | Contact
Us | Site
Map |
